(NASDAQ: GOSS) Gossamer Bio's forecast annual revenue growth rate of 27.26% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.97%.
Gossamer Bio's revenue in 2026 is $55,537,000.On average, 10 Wall Street analysts forecast GOSS's revenue for 2026 to be $5,856,845,692, with the lowest GOSS revenue forecast at $0, and the highest GOSS revenue forecast at $11,582,261,467. On average, 10 Wall Street analysts forecast GOSS's revenue for 2027 to be $14,947,571,441, with the lowest GOSS revenue forecast at $4,554,046,637, and the highest GOSS revenue forecast at $30,064,593,596.
In 2028, GOSS is forecast to generate $27,492,322,356 in revenue, with the lowest revenue forecast at $5,015,459,525 and the highest revenue forecast at $87,292,934,755.